Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year High - Time to Buy?
Market Beat·- Telix Pharmaceuticals reached a new 52-week high of $12.7070 following the US FDA approval of Pixclara for brain cancer imaging. - The company maintains a consensus Moderate Buy rating from analysts with a target price of $20.40. - Institutional investors and hedge funds actively adjusted their stakes in the biopharmaceutical firm during recent quarters.